Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 379,145
  • Shares Outstanding, K 204,943
  • Annual Sales, $ 15,450 K
  • Annual Income, $ -111,570 K
  • EBIT $ -82 M
  • EBITDA $ -81 M
  • 60-Month Beta 0.79
  • Price/Sales 24.54
  • Price/Cash Flow N/A
  • Price/Book 4.27

Options Overview Details

View History
  • Implied Volatility 143.22% ( +18.04%)
  • Historical Volatility 160.27%
  • IV Percentile 53%
  • IV Rank 32.76%
  • IV High 404.32% on 01/17/24
  • IV Low 16.01% on 12/22/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 205
  • Volume Avg (30-Day) 277
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 4,248
  • Open Int (30-Day) 3,841

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.09
  • Prior Year 0.35
  • Growth Rate Est. (year over year) -122.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8000 +2.78%
on 12/20/24
3.3100 -44.11%
on 12/02/24
-0.1600 (-7.96%)
since 11/20/24
3-Month
1.1900 +55.46%
on 11/05/24
3.3100 -44.11%
on 12/02/24
-0.3000 (-13.95%)
since 09/20/24
52-Week
1.1900 +55.46%
on 11/05/24
4.3200 -57.18%
on 06/13/24
+0.4300 (+30.28%)
since 12/20/23

Most Recent Stories

More News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TSHA : 1.8500 (unch)
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.

ACHC : 37.90 (-1.79%)
NGNE : 22.64 (+2.56%)
ACAD : 16.87 (+0.84%)
TSHA : 1.8500 (unch)
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TSHA : 1.8500 (unch)
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

TSHA : 1.8500 (unch)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TSHA : 1.8500 (unch)
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

TSHA : 1.8500 (unch)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TSHA : 1.8500 (unch)
3 Growth Stocks That Could Go Parabolic in 2024

These innovation-oriented companies could take flight this year.

ABCL : 2.85 (+5.17%)
CERS : 1.5800 (unch)
TSHA : 1.8500 (unch)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Taysha Gene Therapies, Inc. (NASDAQ: TSHA) for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

TSHA : 1.8500 (unch)
2 Healthcare Stocks That More Than Tripled Recently. Can They Keep Climbing?

These highly volatile stocks recently rocketed higher, but what are the chances that they'll be able to provide further gains?

CGC : 2.83 (+4.43%)
TSHA : 1.8500 (unch)

Business Summary

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104...

See More

Key Turning Points

3rd Resistance Point 2.0583
2nd Resistance Point 1.9967
1st Resistance Point 1.9233
Last Price 1.8500
1st Support Level 1.7883
2nd Support Level 1.7267
3rd Support Level 1.6533

See More

52-Week High 4.3200
Fibonacci 61.8% 3.1243
Fibonacci 50% 2.7550
Fibonacci 38.2% 2.3857
Last Price 1.8500
52-Week Low 1.1900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar